Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions

Author： Bredberg E.   Andersson T.B.   Frison L.   Thuresson A.   Johansson S.   Eriksson-Lepkowska M.   Larsson M.   Eriksson U.G.  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.42, Iss.8, 2003-01, pp. : 765-777

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cytochrome P450-mediated cardiovascular drug interactions

By Scheen André J  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 9, 2011-09 ,pp. : 1065-1082

Informa Healthcare

Access to resources Recommend Favorite

The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins

By Worz Chad R   Bottorff Michael  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 7, 2001-07 ,pp. : 1119-1127

Informa Healthcare

Access to resources Recommend Favorite

Emerging In Vitro Tools to Evaluate Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions

By  

Current Drug Discovery Technologies, Vol. 7, Iss. 3, 2010-09 ,pp. : 199-222

Bentham Science Publishers

Access to resources Recommend Favorite

Selective Serotonin Reuptake Inhibitors and Cytochrome P-450 Mediated Drug-Drug Interactions: An Update

By  

Current Drug Metabolism, Vol. 3, Iss. 1, 2002-02 ,pp. : 13-37

Bentham Science Publishers

Access to resources Recommend Favorite

Heterotropic Cooperativity of Cytochrome P450 3A4 and Potential Drug-Drug Interactions

By  

Current Drug Metabolism, Vol. 2, Iss. 2, 2001-06 ,pp. : 185-198

Bentham Science Publishers

Access to resources Recommend Favorite